According to a recent LinkedIn post from Cala Health, the company’s team participated in the 3rd International Tremor Congress in Tampa, engaging with movement disorder specialists and neurologists on advances in tremor research. The post notes that founder Kate Rosenbluth, Ph.D., and clinician collaborators presented updates on clinical evidence for wearable neuromodulation in TAPS therapy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also describes a presentation on how noninvasive TAPS may treat refractory essential tremor, citing electrophysiologic evidence of VIM modulation and PET-based network effects. For investors, this scientific visibility and focus on clinical data could signal progress toward deeper clinician adoption, potential differentiation within neuromodulation therapies, and support for future reimbursement or commercialization efforts in the essential tremor market.